Kidney Cancer Trial, Recruiting NCT06886282 Sponsor: National Cancer Institute, Naples Condition: Kidney Cancer
Back to Kidney Cancer

Kidney Cancer Trial, Recruiting

NCT06886282
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older
  • People with a life expectancy of more than 3 months
  • People who have been diagnosed with colorectal cancer (Stage I or II) confirmed by a tissue sample analysis
  • People whose cancer is classified as T1–T3, N0, M0 (meaning the tumour is limited in size, has not spread to lymph nodes, and has not spread to other organs), and who are considered suitable for surgery
  • People who are able to understand and sign a consent form agreeing to take part
  • People who are clinically stable, with no significant changes in kidney function or treatment in the weeks before joining the trial
  • For people without chronic kidney disease: People with adequate liver, kidney, and bone marrow function, including acceptable levels of certain blood markers (haemoglobin, platelets, creatinine, and bilirubin)
  • For people with chronic kidney disease: People with a confirmed chronic kidney disease diagnosis lasting at least 3 months (as defined by international kidney disease guidelines), and a kidney filtration rate of 60 ml/min/1.73m² or below (confirm with trial site)

Who may not be able to join:

  • People who have recently experienced acute (sudden) kidney failure
  • People who have had a kidney transplant, have autoimmune diseases, have inflammatory bowel disease, or have conditions beyond colorectal cancer or blood-related cancers
  • People who have recently used steroids or immunosuppressant medications, or who have had a cardiovascular event (such as a heart attack or stroke) within the 3 months before joining
  • People with a history of serious allergic reactions to iodinated contrast agents or gadolinium-based contrast agents (types of dyes used in medical imaging)
  • People who have had, or are planning to have, invasive or surgical procedures within 3 months of joining that could interfere with the study
  • People with psychiatric conditions that could affect their ability to follow study procedures or provide informed consent
  • People who have had another type of cancer in the 5 years before joining the trial
  • People who are pregnant or breastfeeding (pregnancy will be checked before enrolment using a urine or blood test)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +39 3687859032

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
National Cancer Institute, Naples
Registry
ClinicalTrials.gov
Start date
5 November 2024
Est. completion
31 August 2026

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Identification of specific biomarkers by transcriptomic study

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov